Today's Date: June 3, 2023
Bijou Ikli named new CEO by Florida Assisted Living Association   •   Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemo   •   KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line   •   San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat   •   Statement from Minister Hutchings on progress in support of rural Canadians   •   Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research   •   The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve   •   Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf   •   Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i   •   UNice Celebrates LGBTQ Pride Month   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin   •   Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i   •   Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting   •   Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery   •   56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award   •   Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Cl
Bookmark and Share

SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los

NEW ORLEANS , March 25 /Businesswire/ - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 27, 2023 to file lead plaintiff applications in a securities class action lawsuit against Sotera Health Company (NasdaqGS: SHC), if they purchased or otherwise acquired the Company’s shares (i) pursuant and/or traceable to the Company’s November 2020 initial public offering (the “IPO”); (ii) pursuant and/or traceable to the Company’s March 2021 secondary public offering (the “SPO,” and together with the IPO, the “Offerings”); and/or (iii) between November 20, 2020 and September 19, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Ohio.

What You May Do

If you purchased or acquired shares of Sotera as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-shc/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by March 27, 2023.

About the Lawsuit

Sotera and certain of its executives are charged with failing to disclose material information during the Class Period and/or in the Registration Statement and Prospectus issued in conjunction with the Offerings, violating federal securities laws.

On September 19, 2022, a jury presiding over the first lawsuit against the Company to go to trial arising from the Company’s Ethylene Oxide (“EtO”) emissions held it liable for “willful and wanton” misconduct in failing to prevent toxic EtO emissions and failing to warn about the severe health hazard posed by them, which caused the plaintiff’s cancer condition.

On this news, the price of Sotera’s shares plummeted, falling by $4.90 per share or approximately 33.3%.

The case is Oakland County Employees’ Retirement System and Oakland County Voluntary Employees’ Beneficiary Association v. Sotera Health Company, No. 23-cv-143.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.


STORY TAGS: United States, North America, Class Action Lawsuit, Professional Services, Legal, Louisiana, Lawsuit,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News